Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
Ewm8jsVHFQNjjvxL
